Sirtex Medical (ASX:SRX) is an Australian global life-sciences company developing and delivering effective oncology treatments through innovative small particle technology.

Considered a global leader within the rapidly growing market of Interventional Oncology, this field of interventional radiology deals with the diagnosis and treatment of cancer using targeted and minimally-invasive procedures.

After a challenging 2017, the company has worked hard to restore shareholder value and grow earnings.

In this podcast CEO Andrew McLean discusses this turnaround, and the markets Sirtex Medical is making strides in.

Recommended Posts